Myxoid liposarcoma of the head and neck is an extremely rare entity. The scalp region represents a risk factor to the patient because the diagnosis is usually made late, and the surgeon must have ...
for lete-cel for the treatment of advanced or metastatic synovial sarcoma and myxoid/round cell liposarcoma (MRCLS) by the end of 2025. Data from the Phase II IGNYTE-ESO trial (NCT03967223 ...
Next up for Adaptimmune is a filing next year for a second T-cell therapy, NY-ESO-1-targetting letetresgene autoleucel or lete-cel, for synovial sarcoma and myxoid/round cell liposarcoma (MRCLS).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback